Alzheimer’s & Dementia | November 12, 2022

Ashton NJ, Puig-Pijoan A, Milà-Alomà M, Fernández-Lebrero A, García-Escobar G, González-Ortiz F, Kac PR, Brum WS, Benedet AL, Lantero-Rodriguez J, Day TA, Vanbrabant J, Stoops E, Vanmechelen E, Triana-Baltzer G, Moughadam S, Kolb H, Ortiz-Romero P, Karikari TK, Minguillon C, Hernández Sánchez JJ, Navalpotro-Gómez I, Grau-Rivera O, María Manero R, Puente-Periz V, de la Torre R, Roquer J, Dage JL, Zetterberg H, Blennow K and Suárez-Calvet M

Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2022

https://doi.org/10.1002/alz.12841

This study was performed using Simoa Homebrew assay(s).

Abstract

Introduction

Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences.

Methods

In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer’s disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio.

Results

All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94).

Discussion

Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD.